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Abstract 36 
Background: Results of treatment of severe T Lymphocyte immunodeficiencies by haematopoietic 37 
stem cell transplantation (HSCT) have improved. T cell depleted (TCD) haplo-identical transplants 38 
are successful if there is no HLA-identical donor. Methods to remove T lymphocytes include 39 
addition of anti-CD52 antibodies and CD34+ positive HSC-selection. 40 
Objective: Assessment of long-term immune function is important following these treatments. We 41 
looked at immune reconstitution in 36  survivors > 2 years following HSCT for severe T 42 
Lymphocyte immunodeficiencies and compared engraftment quality between the two T lymphocyte 43 
depletion methods. 44 
Methods: Chimerism, T and B lymphocyte subsets immunoglobulin level and specific antibody 45 
production at last follow up, were examined. The χ2 (Fishers exact test) and Wilcoxon rank sum 46 
analyses were used to compare the groups. 47 
Results: Nineteen patients received anti-CD52-treated and 19 anti-CD34-treated HSC. More anti-48 
CD52-treated patients had full donor myeloid chimerism (p=0.025). All patients developed full 49 
donor T lymphocyte chimerism. There was no difference in donor B lymphocyte chimerism, but 50 
significantly more anti-CD52-treated patients had class switched memory B lymphocytes 51 
(p=0.024), normal IgG levels and normal responses to tetanus and Haemophilus influenzae type B 52 
vaccination. More anti-CD52-treated patients with common gamma chain or JAK3 SCID had donor 53 
B lymphocytes. 54 
Conclusion: Long-term T lymphocyte function is good with either treatment method, with low 55 
incidence of graft versus host disease. The results imply more incomplete donor chimerism in anti-56 
CD34-treated  patients with less B lymphocyte function. 57 
Clinical implications: Retention of cells other than HSC in the manipulated marrow may result in 58 
more complete engraftment and immune function. 59 
 (250 words) 60 
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Capsule summary: 61 
We show good long-term immune function to 19 years post-transplant following T lymphocyte-62 
depleted marrow transplantation for severe T lymphocyte immunodeficiency: results suggest T 63 
lymphocyte-depletion method may influence establishment of donor chimerism. 64 
 65 
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Abbreviations 70 
HSCT, haematopoietic stem cell transplantation 71 
HSC, haematopoietic stem cell  72 
GvHD, graft versus host disease 73 
Hib, Haemophilus influenzae type B 74 
TEE, Thymic emigrant equivalent 75 
FISH, fluorescent in-situ hybridisation 76 
CγC, common gamma chain 77 
IL7Rα, interleukin 7 receptor alpha 78 
JAK3, janus-associated kinase 3 79 
SCID, severe combined immunodeficiency 80 
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Introduction 81 
Severe combined immunodeficiencies are inherited genetic defects in T lymphocyte differentiation 82 
with or without defects in other lymphoid (B and natural killer cell) or myeloid lineages [1].  83 
Conventional treatment for these disorders is haematopoietic stem cell transplantation (HSCT). 84 
Improvements in tissue typing, advances in stem cell manipulation, new chemotherapy conditioning 85 
regimens as well as new methods for detecting and treating viral and fungal infection have led to 86 
improving survival and cure over the past two decades [2].  87 
 88 
For many patients without an HLA identical relative or unrelated donor the use of T lymphocyte 89 
depleted haematopoietic stem cells (HSC) from an HLA mismatched donor has been successful 90 
with survival rates of 75-85% [3,4].  A number of methods have been employed to remove viable T 91 
lymphocytes from the graft including the use of E-rosette lectin depletion and in vitro CAMPATH-92 
1M anti-lymphocyte antibodies (anti-CD52).  Since the late 1990s European centres performing T 93 
lymphocyte depleted HSCT for patients with primary immunodeficiency have used CD34+ positive 94 
stem cell selection rather than T lymphocyte depletion. The most commonly used method, the 95 
Miltenyi CliniMACS® system, uses an organic iron bead attached to an anti-CD34 antibody to 96 
isolate purified CD34+ HSC from the other cells, by passing the HSC source through a magnetic 97 
column [5].  The purified CD34+ HSC fraction is infused into the patient. Using this method, 4 log 98 
depletions of T lymphocyte numbers can be achieved.  99 
 100 
There are important differences between CD34+ positive stem cell selected and T lymphocyte 101 
depleted bone marrow. Whilst the residual T lymphocyte count in anti-CD52-treated marrow may 102 
be relatively high, very few of the T lymphocytes remain viable as they are still coated with anti-103 
CD52 when infused into the recipient and are then destroyed by complement-mediated lysis. In the 104 
anti-CD34-treated HSC product, although the number of T lymphocytes infused into the patient 105 
may be very low, those that are infused are viable and could cause graft versus host disease 106 
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(GvHD).  Additionally the anti-CD52-treated product will contain component blood cell precursors 107 
and cells already in early differentiation from the stem cell, as well as other stromal factors that may 108 
aid engraftment of HSC into the bone marrow space [6] thus achieving “better” engraftment.  109 
 110 
We have previously published the results of the long term follow up of 19 children who received 111 
anti-CD52-treated marrow, transplanted between 1987- 1998 [7].  It was subsequently noted that 112 
since changing to CD34+ positive stem cell selection of marrow, more patients failed to develop B 113 
lymphocyte function. Results of long-term follow up of all these patients are presented, particularly 114 
comparing the quality of engraftment in patients receiving anti-CD52-treated HSC with those given 115 
CD34+ selected HSC.   116 
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Methods 117 
A retrospective review was performed of all patients undergoing HSCT for severe T Lymphocyte 118 
immunodeficiencies who had survived > 2 years treated at our centre with either anti-CD52-treated 119 
or anti-CD34-treated HSCT. Anti-CD52- and anti-CD34- treatment was performed on whole, 120 
freshly harvested marrow as previously described [5, 8].  121 
 122 
The following parameters were analysed: myeloid chimerism, T lymphocyte number and 123 
chimerism, CD3+/CD4+/CD45RA+/CD27+  and CD3+/CD4-/CD45RA+/CD27+ (naïve) T 124 
lymphocyte numbers, B lymphocyte number and chimerism, memory B lymphocyte 125 
(CD19+/CD27+/IgM+) and class switched memory B lymphocyte (CD19+/CD27+/IgM-) number, 126 
and serum IgG, IgA and IgM level, as well as specific antibody levels to tetanus toxoid, 127 
Haemophilus influenzae type B (Hib) and pneumococcal polysaccharide antigens following 128 
vaccination. 129 
 130 
Lymphocyte subset analysis was measured by 4 colour flow cytometry as previously described [9]. 131 
Briefly, lymphocyte surface marker studies were performed on fresh whole blood collected in 132 
EDTA, using appropriate markers (CD45 PerCP, CD3 FITC, CD4 APC, CD8 PE, CD19 APC, 133 
CD16/CD56 PE, CD3 PerCP/ CD4 APC/CD45RAFITC/CD27 PE, CD19 PerCP/CD27 FITC/IgM 134 
APC/IgD PE (Becton Dickinson, UK Ltd, Oxford)), and analysed on a Becton Dickinson 135 
FACSCalibur flow cytometer. The T and B lymphocyte numbers were defined as normal or low 136 
using age-specific reference ranges. Class-switched memory B lymphocytes were defined as <1% 137 
or > 1% of the B cell population. The markers CD3+/CD4+/CD45RA+/CD27+ and CD3+/CD4-138 
/CD45RA+/CD27+ were used as surrogates for recent thymic emigrant T lymphocytes  (thymic 139 
emigrant equivalent TEE) [10]. Briefly, the CD3 subset was gated and 140 
CD4+/CD45RABRIGHT+/CD27+ lymphocytes identified. It was assumed that the majority of CD4- 141 
lymphocytes in this population were CD8+. By identifying CD4-CD45RA+CD27+ lymphocytes, 142 
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effector cells (which are CD45RA+CD27-), were excluded. We have previously demonstrated that 143 
the CD45RABRIGHT+/CD27+ lymphocyte population correlates with CD45RO- lymphocytes 144 
(unpublished observations).  Lymphocytes were described as present or absent. Lymphocyte 145 
responses to stimulation with phytohaemagglutinin were performed using standard tritiated 146 
thymidine uptake methods and measured as a percentage of the response of a healthy adult control 147 
[7]. Immunoglobulin concentrations were measured by rate nephelometry, and specific antibody 148 
responses to tetanus toxoid, Haemophilus influenzae type B conjugate vaccine and pneumococcal 149 
polysaccharide vaccine antigens were measured by Enzyme-Linked ImmunoSorbent Assay [11]. 150 
Immunoglobulin levels were defined as normal or low using age-specific reference ranges and 151 
specific antibody levels were defined as present or absent after vaccination. 152 
 153 
Cells were separated into separate lineages prior to measuring chimerism. Whole blood was stained 154 
with CD3, CD19 or CD15 micro beads and cell lines were separated using an autoMACS 155 
automated bench-top magnetic cell sorter (Miltenyi Biotec Ltd, Surrey, UK). Chimerism was 156 
measured in sex-mismatched cases by XY-fluorescent in-situ hybridisation (FISH) using standard 157 
cytogenetic techniques. Briefly, interphase FISH was performed using a Vysis 2-colour CEP 158 
X/CEP Y probe set according to the manufacturers protocol. Where donor and recipient were same 159 
sex, chimerism was measured by short tandem repeat marker analysis of genomic DNA, as 160 
previously described [12] – sensitivity was accurate to within 5%. For the purposes of analysis, 161 
chimerism was defined as donor, mixed or recipient in specific cell lineages. 162 
 163 
Patients, when given cytoreductive chemotherapy, were treated in accordance with the European 164 
Group for Blood and Marrow Transplantation/European Society for Immunodeficiencies Inborn 165 
Errors Working Party treatment guidelines current at time of transplantation. No patients received 166 
radiotherapy. Nucleated cell doses in the stem cell products were compared between groups, as 167 
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CD34+ cell doses were not available for many of the earliest patients who received anti-CD52-168 
treated marrow.  169 
 170 
The χ2 (Fishers exact test) and non-parametric Wilcoxon rank sum analyses were used to detect 171 
statistical differences between the groups (GB-Stat PPCworks 6.5.4, Dynamic Microsystems Inc, 172 
Silver Spring, MD) – a 2 sided p value of ≤ 0.05 was considered to be significant. 173 
 174 
Patient Characteristics 175 
From May 1987 until the end of August 2004, 72 patients with severe T Lymphocyte 176 
immunodeficiencies  were transplanted with 57 (79%) survivors; 47 patients underwent T 177 
lymphocyte depleted HSCT, of whom 36 survive (77%). Prior to 1999, marrow from HLA-178 
mismatched donors was depleted in vitro with anti-CD52 antibody (27 patients). Subsequently 179 
marrow has been CD34+ stem cell selected as described above (22 patients). All patients surviving 180 
> 2 years from transplantation for severe T Lymphocyte immunodeficiencies, who were still alive at 181 
the time of the study, were included. 182 
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Results 183 
Patient characteristics are detailed (Table 1); there were 19 long term survivors in each group. Two 184 
patients (12, 13) in the anti-CD52 group were re-transplanted using CD34+ HSC. There were 8 185 
deaths in the anti-CD52-treated group (3 fungal infection, 3 parainfluenzae pneumonitis, 1 186 
cytomegalovirus pneumonitis, 1 idiopathic pneumonitis; median time at death 2.5 months post-187 
HSCT, range 5 days – 7 months), and 3 in the anti-CD34-treated group (1 hepatic veno-occlusive 188 
disease, 1 Epstein Barr viral infection, 1 adenovirus infection; time at death 3 days – 1 month post-189 
HSCT). There were no deaths associated with GvHD in either group. Of the survivors, 10 had 190 
common gamma chain deficient (CγC) severe combined immunodeficiency (SCID), 8 had T-191 
B+NK+ SCID (3 confirmed interleukin 7 receptor alpha chain (IL7Rα) defects), 8 had recombinase 192 
activating gene 2 or artemis deficiency, 3 had adenosine deaminase SCID, 3 had janus-associated 193 
kinase (JAK) 3 deficiency, 2 had zeta-associated protein 70 kinase deficiency and 4 had other 194 
phenotypes. There was no significant difference in the number of patients in each group who 195 
received fully myeloablative cytoreductive chemotherapy with busulphan 16mg/kg and 196 
cyclophosphamide 200mg/kg. 197 
 198 
There was no significant difference in age at transplantation between the groups (anti-CD52-treated 199 
group median 7 months, range 1.25-17 months;- anti-CD34-treated group median 6 months, range 200 
1-25 months). The anti-CD52-treated group had significantly longer follow up than the anti-CD34-201 
treated group (median 12.83 years, range 1.17 – 18.92 years versus median 5.92 years, range 2.67 – 202 
8.17 years, p <0.0001). The anti-CD52-treated group received significantly higher nucleated cell 203 
doses (median 5 x107/kg range 0.4 – 525 x107/kg versus median 0.13 x107/kg, range 0.0114 – 0.57 204 
x107/kg, p < 0.0001) and T lymphocyte doses (median 225 x103/kg range 0 – 6690 x103/kg versus 205 
median 15 x103/kg, range 2.2 – 180 x103/kg, p = 0.0001) respectively. Three patients in each group 206 
received a ‘boost’ infusion of T lymphocyte depleted HSC from the original donor, without further 207 
chemotherapy, for incomplete chimerism [13]. There was no significant difference in survival 208 
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between the groups (70% vs 86%, p = 0.19) and no late deaths (> 12 months post-HSCT) in either 209 
group. Only four patients in the anti-CD52-treated HSC group, and 1 in the anti-CD34-treated HSC 210 
group had grade I acute GvHD of the skin, and one patient in each group had mild localised chronic 211 
GvHD of the skin. 212 
 213 
Chimerism and Immune Reconstitution 214 
There was no significant difference in the number of patients who achieved some donor myeloid 215 
chimerism between the two groups (Table 2). However, significantly more patients who received 216 
anti-CD52-treated HSC had full donor myeloid chimerism (7 vs 1, p=0.025) (figure 1). More anti-217 
CD34-treated HSC patients with some donor myeloid chimerism received a fully myeloablative 218 
dose of busulphan (16mg/kg) than anti-CD52-treated HSC patients (8 vs 2, p=0.03).  All patients in 219 
both groups developed full donor chimerism in the T lymphocyte lineage. Following immune 220 
reconstitution, all anti-CD34-treated HSC patients had TEE cells compared to 15/19 in the anti-221 
CD52-treated HSC group. Neither the B lymphocyte number, nor the number of patients with at 222 
least some donor B lymphocyte chimerism at last follow up was significantly different between the 223 
two groups. However, more patients who had received anti-CD52-treated HSC had class switched 224 
memory B lymphocytes (15 vs 9, p=0.024). There was no difference between the groups in the 225 
number of patients who had normal levels of IgM or IgA at latest follow up. However, significantly 226 
more patients who had received anti-CD52-treated HSC had normal IgG levels (16 vs 10, p = 227 
0.036). Correlating with this, at time of last follow-up, more patients in the anti-CD52-treated HSC 228 
group had achieved a sustained response to tetanus toxoid vaccination (16 vs 10, p=0.036) and to 229 
Hib conjugate vaccine (16 vs 9, p= 0.019). There was no difference between groups in patients 230 
mounting a response to pneumococcal polysaccharide antigen. More patients in the anti-CD34-231 
treated HSC group had CγC/JAK3 deficient SCID (4 vs 9, p=0.09). None of these patients with 232 
CγC/JAK3 deficient SCID in either group received busulphan 16mg/kg, and there was no difference 233 
in the number of these patients receiving no conditioning compared to busulphan 8mg/kg. The 234 
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numbers of CγC/JAK3 SCID patients were too small to make confident comparisons, but 235 
significantly more CγC/JAK3 SCID patients had donor B lymphocytes in the anti-CD52-treated 236 
HSC group (3/4 vs 2/9, p=0.014).  237 
 238 
Complications 239 
Four patients developed a single significant invasive infection > 2 years following transplantation. 240 
Four developed planar warts, only 2 of whom had CγC or JAK3-deficient SCID – in no patient 241 
were they severe or persistent. Four developed autoimmunity, 2 of whom had autoimmune thyroid 242 
disease (Table 1). There was no late GvHD, except for patient 13 who had chronic skin GvHD after 243 
the first transplant. Six patients had mild to moderate behaviour-related problems, only one of 244 
whom had adenosine deaminase SCID.  245 
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Discussion 246 
This study adds to those previously reporting long term follow up of SCID patients receiving T 247 
lymphocyte depleted HSCT [14, 15], but is the first to compare quality of immune reconstitution 248 
after anti-CD52- or anti-CD34-treated HSCT in severe T lymphocyte disorders. Our overall 249 
survival of 77% compares favourably with other reported series [4, 16]. Overall survival was better 250 
in the anti-CD34-treated HSC group, but there was no significant difference between the two 251 
groups. This improvement over time is likely to reflect improvement in transplant care, including 252 
more accurate diagnoses, earlier detection of viral and fungal infections by PCR, with new, more 253 
effective treatments, and better supportive care, as has been demonstrated in other studies [2], rather 254 
than differences in the method of marrow manipulation. Whilst follow up was longer in patients 255 
receiving anti-CD52-treated HSC, no deaths occurred beyond 12 months in either group.  256 
 257 
The T lymphocyte depletion method employed to manipulate the graft does not appear to affect T 258 
lymphocyte chimerism. Interestingly, there were more patients in the anti-CD34-treated HSC group 259 
who had TEE T lymphocytes. A recent study has demonstrated that TEE lymphocytes may be 260 
found in the absence of myeloid engraftment, particularly in patients with CγC/JAK3 SCID [14], of 261 
which there were more in our anti-CD34-treated HSC group: our study appears to support this 262 
observation. We did not have data comparing the speed of T lymphocyte immune reconstitution 263 
between the two marrow manipulation methods, particularly with appearance of TEE T 264 
lymphocytes. However, previous studies have indicated that the appearance of recent thymic 265 
emigrants is similar for patients who received replete or TCD HSCT [17]. 266 
 267 
Although, overall, there was no statistical difference in B lymphocyte donor chimerism between the 268 
two groups, there was a trend to more complete B lymphocyte donor chimerism in the anti-CD52-269 
treated HSC group. Over a longer period of time, humoral function may improve so that those 270 
transplanted longest have better antibody responses. It was not possible to investigate this further, as 271 
  SLATTER 
 
14 
14 
the early data in the anti-CD52-treated HSC patients was incomplete. However, all but 3 patients (8, 272 
12, 13) in the anti-CD52-treated group had discontinued immunoglobulin replacement by 4 years 273 
post HSCT [7]. It therefore seems unlikely that many of our patients who received anti-CD34-274 
treated HSC, but remain on immunoglobulin treatment, will develop humoral immunity in the 275 
future.  More likely, antibody function post-transplant may depend on the type of SCID and the 276 
chimeric state [18]. Recipient B lymphocytes in IL7Rα deficient SCID are functionally normal, 277 
whereas those from CγC or JAK3 deficient SCID are intrinsically defective [19]. Therefore, unless 278 
donor B lymphocyte chimerism is achieved in patients with CγC or JAK3 deficient SCID, normal 279 
humoral function is unlikely as interaction with donor T lymphocytes does not result in 280 
immunoglobulin class switching and antigen-specific IgG production in recipient B lymphocytes 281 
[20]. Our results are difficult to interpret, as more patients in the anti-CD34-treated HSC group had 282 
CγC /JAK3 SCID with recipient B lymphocytes. There were more patients with CγC /JAK3 SCID 283 
who achieved donor B lymphocyte chimerism in the anti-CD52-treated HSC group, despite the fact 284 
that there was no difference in the conditioning regimens employed for the CγC/JAK3 deficient 285 
patients, and none received full myeloablative chemotherapy. Patient 1, with CγC deficiency has 286 
normal humoral immunity, apparently with recipient B lymphocytes –– it may be that the methods 287 
of detecting donor chimerism were not sensitive enough to detect very low levels of chimerism 288 
(<5%), or that there is a significant population of donor B lymphocytes in lymphoid tissue. More 289 
sensitive methods of detecting microchimerism may detect donor cells in this patient [19]. Patient 8, 290 
with IL7Rα deficiency does not make immunoglobulin, although donor T lymphocytes would be 291 
expected to interact with recipient B lymphocytes. In this patient, T lymphocyte engraftment is 292 
poor, with few TEE and a restricted T lymphocyte repertoire (data not shown); there may be too 293 
few T and B lymphocyte interactions for effective humoral immunity. Patient 14, with Artemis 294 
deficiency has complete donor B lymphocyte engraftment with recipient myeloid engraftment. 295 
Donor early B lymphocyte pre-cursors may have a competitive advantage over recipient B 296 
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lymphocyte pre-cursors which are blocked at an early stage in B lymphocyte development, enabling 297 
chimerism of donor mature B lymphocytes. 298 
 299 
There is an impression of better donor stem cell engraftment with overall more complete donor 300 
myeloid and B lymphocyte engraftment in patients who received anti-CD52-treated HSC. This 301 
implies superior stem cell engraftment and perhaps better long-term immune function; a continuing 302 
longitudinal study is needed to see if there is a greater waning of immune function in the anti-303 
CD34-treated HSC group compared to the anti-CD52-treated HSC group.  This observation is 304 
perhaps surprising in that fewer patients in the anti-CD52-treated HSC group received full 305 
myeloablative conditioning with busulphan 16mg/kg, which is more likely to result in myeloid 306 
engraftment. The depletion of most additional marrow cells, other than CD34+ HSC may have 307 
unintended drawbacks for engraftment, as some of the other cellular elements may aid marrow 308 
engraftment of stem cells. Other methods of marrow manipulation such as CD3/CD19 depletion 309 
may result in decreased GvHD risk, without compromising engraftment [21]. 310 
 311 
As new information appears, the determinants of successful outcome of transplantation for SCID 312 
are becoming clearer. Long-term T lymphocyte immunity appears to require early, sustained thymic 313 
output of donor T lymphocytes [14-16, 22, 23]. There is growing evidence of a correlation between 314 
myeloid chimerism, TRECs and naïve T lymphocytes, although that may be less important for 315 
patients with CγC/JAK3 SCID [14, 16, 17]. Further very long-term studies are required to confirm 316 
these observations, but if there is no good evidence of newly emerging thymic T lymphocytes early 317 
post-HSCT, then long-term T lymphocyte engraftment and function is likely to be poor [16]. In 318 
these instances, early intervention with further therapeutic measures is more likely to be successful, 319 
before thymic atrophy is established [22, 23]. As for B lymphocyte function, our study shows the 320 
correlation between class switched memory B lymphocytes and antigen-specific IgG production, 321 
and these markers should be considered an indication of long-term B lymphocyte function. The 322 
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advantages and disadvantages of chemotherapy continue to be debated [1, 4,19]. The role of 323 
cytoreductive chemotherapy in achieving long term immune reconstitution is becoming more clear 324 
[24], and is confirmed in our study. It is of note that all patients who require continued 325 
immunoglobulin replacement received a less myeloablative dose of busulphan 8mg/kg. Whilst the 326 
short-term risks of gene therapy, particularly for CγC SCID have been recognised [25], it will be 327 
important to compare long-term outcomes for HSCT and gene therapy. In particular, comparison 328 
between conditioned and non-conditioned HSCT with gene therapy will be required, and the 329 
molecular defect for which treatment has been given, as well as the method of HSC manipulation 330 
should be considered as our data suggest this may effect the outcome. 331 
 332 
Autoimmunity was seen in 4 of our patients and has been previously reported, as has late occurring 333 
infection [15, 24, 26]. The mechanism of autoimmunity in this setting is unclear, presumably 334 
multifactorial, but there may be a role for subsets of T lymphocytes [27].  Other than a requirement 335 
for continuing immunoglobulin replacement, no other significant long term sequelae were observed.  336 
 337 
Whilst in the first years following TCD HSCT as treatment for severe T lymphocyte deficiency, 338 
long-term survival was the aim of successful treatment, quality of engraftment, long-term 339 
immunoreconstitution and quality of life are now as important [1, 16, 22, 23]. Our results confirm 340 
that mismatched T lymphocyte depleted HSCT for severe T lymphocyte immunodeficiencies 341 
remains a successful technique with 77% overall survival, and good T lymphocyte function, and 71 342 
% with good humoral immunity. Both techniques of marrow manipulation seem effective, and 343 
vastly reduce the risk of GvHD. There is an impression that the B lymphocyte function may be 344 
better after anti-CD52-treated HSC but further studies with more patients are needed to ascertain 345 
whether T lymphocyte depletion rather than haematopoietic stem cell selection results in more 346 
complete immune function, and in particular, in better B lymphocyte function. 347 
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